Position in REPL
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$0
+$0 QoQ
Shares Held
0
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2023
3 quarters on record
Derivatives in REPL
reported options exposure · as of Mar 31, 2026CallValue
$0
CallShares
0
PutValue
$669,375
PutShares
87,500
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026BOOTHBAY FUND MANAGEMENT, LLC holds $541,743,620 across 143 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABVX |
Abivax S.A.
|
472,961 | $52,664,207 | |
| 2 | RVMD |
Revolution Medicines, Inc.
|
438,595 | $42,653,363 | |
| 3 | EXEL |
Exelixis, Inc.
|
803,866 | $34,477,812 | |
| 4 | PCVX |
Vaxcyte, Inc.
|
522,019 | $30,334,524 | |
| 5 | MLYS |
Mineralys Therapeutics, Inc.
|
1,001,728 | $27,136,811 | |
| 6 | TERN |
Terns Pharmaceuticals, Inc.
|
486,170 | $25,630,882 | |
| 7 | CGEM |
Cullinan Therapeutics, Inc.
|
1,112,803 | $15,812,930 | |
| 8 | XENE |
Xenon Pharmaceuticals Inc.
|
270,412 | $15,724,457 |
All Filings in REPL
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $669,375 | 87,500 | Put | Other | 2026-05-15 | |
| 2023-09-30 | $855,500 | 50,000 | Call | Other | 2023-11-14 | |
| 2023-09-30 | $1,962,517 | 114,700 | Put | Other | 2023-11-14 | |
| 2023-06-30 | $1,618,434 | 69,700 | Put | Other | 2023-08-14 | |
| 2023-06-30 | $1,063,476 | 45,800 | Call | Other | 2023-08-14 | |
| No filing history on record for this holder in this stock. | ||||||